NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
12
Mechanism of Action
B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be…
Clinical Trials (5)
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Started Aug 2022
32 enrolled
Hereditary Angioedema (HAE)
A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema
Started Jan 2021
2 enrolled
Hereditary Angioedema
FIRAZYR General Drug Use-Results Survey (Japan)
Started Nov 2018
179 enrolled
Hereditary Angioedema (HAE)
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
Started Mar 2015
8 enrolled
Hereditary Angioedema (HAE)